Trial Outcomes & Findings for Prostate Cancer Screening in Men With Germline BRCA2 Mutations (NCT NCT02154672)

Last Updated: 2021-02-09

Results Overview

number of patients with a BRCA2 mutation who are diagnosed with prostate cancer

Recruitment status

COMPLETED

Target enrollment

1 participants

Primary outcome timeframe

Up to 3 years

Results posted on

2021-02-09

Participant milestones
Measure	BRCA2 Carriers All men identified to have a BRCA2 mutation as part of the Yale Cancer Genetic Counseling Program will be approached and offered participation in the study via our program newsletter, BRCA listserv, Facebook page and a targeted mailing
Overall Study STARTED	1
Overall Study COMPLETED	1
Overall Study NOT COMPLETED	0

Withdrawal data not reported

Prostate Cancer Screening in Men With Germline BRCA2 Mutations

Baseline characteristics by cohort
Measure	BRCA2 Carriers n=1 Participants All men identified to have a BRCA2 mutation as part of the Yale Cancer Genetic Counseling Program will be approached and offered participation in the study via our program newsletter, BRCA listserv, Facebook page and a targeted mailing
Age, Categorical <=18 years	0 Participants n=5 Participants
Age, Categorical Between 18 and 65 years	1 Participants n=5 Participants
Age, Categorical >=65 years	0 Participants n=5 Participants
Sex: Female, Male Female	0 Participants n=5 Participants
Sex: Female, Male Male	1 Participants n=5 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants
Race (NIH/OMB) Asian	0 Participants n=5 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants
Race (NIH/OMB) Black or African American	0 Participants n=5 Participants
Race (NIH/OMB) White	1 Participants n=5 Participants
Race (NIH/OMB) More than one race	0 Participants n=5 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants
Region of Enrollment United States	1 Participants n=5 Participants

Timeframe: Up to 3 years

number of patients with a BRCA2 mutation who are diagnosed with prostate cancer

Outcome measures
Measure	BRCA2 Carriers n=1 Participants All men identified to have a BRCA2 mutation as part of the Yale Cancer Genetic Counseling Program will be approached and offered participation in the study via our program newsletter, BRCA listserv, Facebook page and a targeted mailing
Number of Prostate Cancer Patients With BRCA2 Mutation Carriers	0 participants

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Adverse event data not reported

Adverse event data not reported

Yale University School of Medicine

Phone: 2037852815